Cathelicidin – A Novel Potential Marker of Pediatric Inflammatory Bowel Disease

References

• Sabino J, Verstockt B, Vermeire S, Ferrante M. New biologics and small molecules in inflammatory bowel disease: an update. Therap Adv Gastroenterol. 2019;12:1756284819853208. doi:10.1177/1756284819853208
   Web of Science ®Google Scholar
• Stange EF, Schroeder BO. Microbiota and mucosal defense in IBD: an update. Expert Rev Gastroenterol Hepatol. 2019;13(10):963–976. doi:10.1080/17474124.2019.1671822
   PubMed Web of Science ®Google Scholar
• Glassner KL, Abraham BP, Quigley EMM. The microbiome and inflammatory bowel disease. J Allergy Clin Immunol. 2020;145(1):16–27. doi:10.1016/j.jaci.2019.11.003
   PubMed Web of Science ®Google Scholar
• Bevins CL. The immune system in IBD: antimicrobial peptides. In: Baumgart DC, editor. Crohn’s Disease and Ulcerative Colitis. Springer, Cham; 2017:75–86.
   Google Scholar
• Lei J, Sun L, Huang S, et al. The antimicrobial peptides and their potential clinical applications. Am J Transl Res. 2019;11(7):3919–3931.
   PubMed Web of Science ®Google Scholar
• van der Does AM, Hiemstra PS, Mookherjee N. Antimicrobial host defence peptides: immunomodulatory functions and translational prospects. Adv Exp Med Biol. 2019;1117:149–171. doi:10.1007/978-981-13-3588-4_10
   PubMed Web of Science ®Google Scholar
• Prasad SV, Fiedoruk K, Daniluk T, Piktel E, Bucki R. Expression and function of host defense peptides at inflammation sites. Int J Mol Sci. 2019;21(1):104. doi:10.3390/ijms21010104
   PubMed Web of Science ®Google Scholar
• Mookherjee N, Anderson MA, Haagsman HP, Davidson DJ. Antimicrobial host defence peptides: functions and clinical potential. Nat Rev Drug Discov. 2020;19(5):311–332. doi:10.1038/s41573-019-0058-8
   PubMed Web of Science ®Google Scholar
• Ahluwalia A, Tarnawski AS. Cathelicidin gene therapy: a new therapeutic option in ulcerative colitis and beyond? Gene Ther. 2013;20(2):119–120. doi:10.1038/gt.2012.23
   PubMed Web of Science ®Google Scholar
• Wehkamp J, Schmid M, Stange EF. Defensins and other antimicrobial peptides in inflammatory bowel disease. Curr Opin Gastroenterol. 2007;23(4):370–378. doi:10.1097/MOG.0b013e328136c580
   PubMed Web of Science ®Google Scholar
• Mookherjee N, Brown KL, Hancock REW, Kastin AJ. Chapter 15 - Cathelicidins. Handbook of Biologically Active Peptides (Second Edition). Academic Press; 2013:77–84.
   Google Scholar
• Fabisiak A, Murawska N, Fichna J. LL-37: cathelicidin-related antimicrobial peptide with pleiotropic activity. Pharmacol Rep. 2016;68(4):802–808. doi:10.1016/j.pharep.2016.03.015
   PubMed Web of Science ®Google Scholar
• Sun L, Wang W, Xiao W, Yang H. The roles of cathelicidin LL-37 in inflammatory bowel disease. Inflamm Bowel Dis. 2016;22(8):1986–1991. doi:10.1097/MIB.0000000000000804
   PubMed Web of Science ®Google Scholar
• Moreno-Angarita A, Aragón CC, Tobón GJ. Cathelicidin LL-37: a new important molecule in the pathophysiology of systemic lupus erythematosus. J Transl Autoimmun. 2020;3:100029. doi:10.1016/j.jtauto.2019.100029
   PubMedGoogle Scholar
• Hooper LV, Alt FW. Chapter 3 - Epithelial Cell Contributions to Intestinal Immunity. Advances in Immunology. Academic Press; 2015:129–172.
   Google Scholar
• Sørensen OE, Follin P, Johnsen AH, et al. Human cathelicidin, hCAP-18, is processed to the antimicrobial peptide LL-37 by extracellular cleavage with proteinase 3. Blood. 2001;97(12):3951–3959. doi:10.1182/blood.V97.12.3951
   PubMed Web of Science ®Google Scholar
• Scheenstra MR, van Harten RM, Veldhuizen EJA, Haagsman HP, Coorens M. Cathelicidins modulate TLR-activation and inflammation. Front Immunol. 2020;11:1137. doi:10.3389/fimmu.2020.01137
   PubMed Web of Science ®Google Scholar
• Kahlenberg JM, Kaplan MJ. Little peptide, big effects: the role of LL-37 in inflammation and autoimmune disease. J Immunol. 2013;191(10):4895–4901. doi:10.4049/jimmunol.1302005
   PubMed Web of Science ®Google Scholar
• Nijnik A, Hancock RE. The roles of cathelicidin LL-37 in immune defences and novel clinical applications. Curr Opin Hematol. 2009;16(1):41–47. doi:10.1097/moh.0b013e32831ac517
   PubMed Web of Science ®Google Scholar
• Kim JM. Antimicrobial proteins in intestine and inflammatory bowel diseases. Intest Res. 2014;12(1):20–33. doi:10.5217/ir.2014.12.1.20
   PubMedGoogle Scholar
• Dombrowski Y, Schauber J. Cathelicidin LL-37: a defense molecule with a potential role in psoriasis pathogenesis. Exp Dermatol. 2012;21(5):327–330. doi:10.1111/j.1600-0625.2012.01459.x
   PubMed Web of Science ®Google Scholar
• Neregård P, Engström M, Agerberth B, Catrina AI. LL-37 is expressed in the inflamed synovium in patients with rheumatoid arthritis and downregulated by TNF inhibitors. Ann Rheum Dis. 2012;71:A12. doi:10.1136/annrheumdis-2011-201230.26
   Web of Science ®Google Scholar
• Schauber J, Rieger D, Weiler F, et al. Heterogeneous expression of human cathelicidin hCAP18/LL-37 in inflammatory bowel diseases. Eur J Gastroenterol Hepatol. 2006;18(6):615–621. doi:10.1097/00042737-200606000-00007
   PubMed Web of Science ®Google Scholar
• Tran DH, Wang J, Ha C, et al. Circulating cathelicidin levels correlate with mucosal disease activity in ulcerative colitis, risk of intestinal stricture in Crohn’s disease, and clinical prognosis in inflammatory bowel disease. BMC Gastroenterol. 2017;17(1):63. doi:10.1186/s12876-017-0619-4
   PubMedGoogle Scholar
• Kusaka S, Nishida A, Takahashi K, et al. Expression of human cathelicidin peptide LL-37 in inflammatory bowel disease. Clin Exp Immunol. 2018;191(1):96–106. doi:10.1111/cei.13047
   PubMed Web of Science ®Google Scholar
• Hase K, Eckmann L, Leopard JD, Varki N, Kagnoff MF. Cell differentiation is a key determinant of cathelicidin LL-37/human cationic antimicrobial protein 18 expression by human colon epithelium. Infect Immun. 2002;70(2):953–963. doi:10.1128/iai.70.2.953-963.2002
   PubMed Web of Science ®Google Scholar
• Levine A, Griffiths A, Markowitz J, et al. Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification. Inflamm Bowel Dis. 2011;17(6):1314–1321. doi:10.1002/ibd.21493
   PubMed Web of Science ®Google Scholar
• Hyams JS, Ferry GD, Mandel FS, et al. Development and validation of a pediatric Crohn’s disease activity index. J Pediatr Gastroenterol Nutr. 1991;12(4):439–447. doi:10.1097/00005176-199105000-00005
   PubMed Web of Science ®Google Scholar
• Turner D, Otley AR, Mack D, et al. Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study. Gastroenterology. 2007;133(2):423–432. doi:10.1053/j.gastro.2007.05.029
   PubMed Web of Science ®Google Scholar
• Hyams JS, Di Lorenzo C, Saps M, Shulman RJ, Staiano A, van Tilburg M. Functional disorders: children and adolescents. Gastroenterology. 2016;150(6):1456–1468. doi:10.1053/j.gastro.2016.02.015
   Web of Science ®Google Scholar
• Krawiec P, Pac-Kożuchowska E. Serum interleukin 17A and interleukin 17F in children with inflammatory bowel disease. Sci Rep. 2020;10(1):12617. doi:10.1038/s41598-020-69567-x
   PubMed Web of Science ®Google Scholar
• Vitali R, Stronati L, Negroni A, et al. Fecal HMGB1 is a novel marker of intestinal mucosal inflammation in pediatric inflammatory bowel disease. Am J Gastroenterol. 2011;106(11):2029–2040. doi:10.1038/ajg.2011.231
   PubMed Web of Science ®Google Scholar
• deZoeten EF, Battista KD, Colson SB, et al. Markers of hypoxia correlate with histologic and endoscopic severity of colitis in inflammatory bowel disease. Hypoxia (Auckl). 2020;8:1–12. doi:10.2147/hp.s219049
   PubMed Web of Science ®Google Scholar
• Palmer NP, Silvester JA, Lee JJ, et al. Concordance between gene expression in peripheral whole blood and colonic tissue in children with inflammatory bowel disease. PLoS One. 2019;14(10):e0222952. doi:10.1371/journal.pone.0222952
   PubMed Web of Science ®Google Scholar
• Gombart AF, Borregaard N, Koeffler HP. Human cathelicidin antimicrobial peptide (CAMP) gene is a direct target of the vitamin D receptor and is strongly up-regulated in myeloid cells by 1,25-dihydroxyvitamin D3. FASEB J. 2005;19(9):1067–1077. doi:10.1096/fj.04-3284com
   PubMed Web of Science ®Google Scholar
• Gubatan J, Mehigan GA, Villegas F, et al. Cathelicidin mediates a protective role of vitamin D in ulcerative colitis and human colonic epithelial cells. Inflamm Bowel Dis. 2020;26(6):885–897. doi:10.1093/ibd/izz330
   PubMed Web of Science ®Google Scholar
• Raftery T, Martineau AR, Greiller CL, et al. Effects of vitamin D supplementation on intestinal permeability, cathelicidin and disease markers in Crohn’s disease: results from a randomised double-blind placebo-controlled study. United European Gastroenterol J. 2015;3(3):294–302. doi:10.1177/2050640615572176
   PubMed Web of Science ®Google Scholar
• Sharifi A, Hosseinzadeh-Attar MJ, Vahedi H, Nedjat S. A randomized controlled trial on the effect of vitamin D3 on inflammation and cathelicidin gene expression in ulcerative colitis patients. Saudi J Gastroenterol. 2016;22(4):316–323. doi:10.4103/1319-3767.187606
   PubMed Web of Science ®Google Scholar
• Zhang L-J, Gallo RL. Antimicrobial peptides. Curr Biol. 2016;26(1):R14–R19. doi:10.1016/j.cub.2015.11.017
   PubMed Web of Science ®Google Scholar
• Foster AJ, Smyth M, Lakhani A, Jung B, Brant RF, Jacobson K. Consecutive fecal calprotectin measurements for predicting relapse in pediatric Crohn’s disease patients. World J Gastroenterol. 2019;25(10):1266–1277. doi:10.3748/wjg.v25.i10.1266
   PubMed Web of Science ®Google Scholar
• Banerjee A, Gupta RC. Chapter 15 - Gastrointestinal Toxicity Biomarkers. Biomarkers in Toxicology. Academic Press; 2014:269–277.
   Google Scholar
• Degraeuwe PL, Beld MP, Ashorn M, et al. Faecal calprotectin in suspected paediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2015;60(3):339–346. doi:10.1097/MPG.0000000000000615
   PubMed Web of Science ®Google Scholar
• Daniluk U, Daniluk J, Krasnodebska M, Lotowska JM, Sobaniec-Lotowska ME, Lebensztejn DM. The combination of fecal calprotectin with ESR, CRP and albumin discriminates more accurately children with Crohn’s disease. Adv Med Sci. 2019;64(1):9–14. doi:10.1016/j.advms.2018.08.001
   PubMed Web of Science ®Google Scholar
• Costa F, Mumolo MG, Ceccarelli L, et al. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn’s disease. Gut. 2005;54(3):364–368. doi:10.1136/gut.2004.043406
   PubMed Web of Science ®Google Scholar
• Lee SH, Kim MJ, Chang K, et al. Fecal calprotectin predicts complete mucosal healing and better correlates with the ulcerative colitis endoscopic index of severity than with the Mayo endoscopic subscore in patients with ulcerative colitis. BMC Gastroenterol. 2017;17(1):110. doi:10.1186/s12876-017-0669-7
   PubMedGoogle Scholar
• Koon HW, Shih DQ, Chen J, et al. Cathelicidin signaling via the Toll-like receptor protects against colitis in mice. Gastroenterology. 2011;141(5):1852–63.e1-3. doi:10.1053/j.gastro.2011.06.079
   PubMed Web of Science ®Google Scholar
• Yoo JH, Ho S, Tran DH, et al. Anti-fibrogenic effects of the anti-microbial peptide cathelicidin in murine colitis-associated fibrosis. Cell Mol Gastroenterol Hepatol. 2015;1(1):55–74.e1. doi:10.1016/j.jcmgh.2014.08.001
   PubMedGoogle Scholar
• Tai EK, Wu WK, Wong HP, Lam EK, Yu L, Cho CH. A new role for cathelicidin in ulcerative colitis in mice. Exp Biol Med (Maywood). 2007;232(6):799–808.
   PubMed Web of Science ®Google Scholar
• Boyapati RK, Rossi AG, Satsangi J, Ho GT. Gut mucosal DAMPs in IBD: from mechanisms to therapeutic implications. Mucosal Immunol. 2016;9(3):567–582. doi:10.1038/mi.2016.14
   PubMed Web of Science ®Google Scholar
• Wang S, Song R, Wang Z, Jing Z, Wang S, Ma J. S100A8/A9 in inflammation. Front Immunol. 2018;9:1298. doi:10.3389/fimmu.2018.01298
   PubMed Web of Science ®Google Scholar
• Zhang X, Wei L, Wang J, et al. Suppression colitis and colitis-associated colon cancer by anti-S100a9 antibody in mice. Front Immunol. 2017;8:1774. doi:10.3389/fimmu.2017.01774
   PubMed Web of Science ®Google Scholar
• Smith ME, Stockfelt M, Tengvall S, Bergman P, Lindén A, Qvarfordt I. Endotoxin exposure increases LL-37 - but not calprotectin - in healthy human airways. J Innate Immun. 2017;9(5):475–482. doi:10.1159/000475525
   PubMed Web of Science ®Google Scholar
• Bierkarre H, Harder J, Cuthbert R, et al. Differential expression of antimicrobial peptides in psoriasis and psoriatic arthritis as a novel contributory mechanism for skin and joint disease heterogeneity. Scand J Rheumatol. 2016;45(3):188–196. doi:10.3109/03009742.2015.1091497
   PubMed Web of Science ®Google Scholar
• Hemshekhar M, Piyadasa H, Mostafa D, Chow LNY, Halayko AJ, Mookherjee N. Cathelicidin and calprotectin are disparately altered in murine models of inflammatory arthritis and airway inflammation. Front Immunol. 2020;11:1932. doi:10.3389/fimmu.2020.01932
   PubMed Web of Science ®Google Scholar